Smith & Nephew plc
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Deepak S. Nath
- Full Time Employees
- 18,362
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- Building 5 Croxley Park Hatters Lane Watford HRT United Kingdom WD18 8YE
- IPO Date
- Nov 16, 1999
- CIK
- 0000845982
- Website
- smith-nephew.com
- Similar Companies
- Business
- Smith & Nephew plc is a medical technology company that develops, manufactures, markets and sells medical devices and services focused on the repair, regeneration and replacement of soft and hard tissue. The company operates through three segments: Orthopaedics, offering hip, knee and shoulder implants for joint replacement, robotics-assisted technologies including the CORI Surgical System, and trauma products such as the EVOS Plating System and AETOS Shoulder System to stabilise fractures and correct deformities; Sports Medicine & ENT, providing advanced instruments for soft tissue repair and removal, including the REGENETEN Bioinductive Implant for rotator cuff tears and extra-articular ligaments, arthroscopic enabling technologies like COBLATION wands, and ENT devices for tonsil and adenoid procedures; and Advanced Wound Management, encompassing negative pressure wound therapy systems such as RENASYS EDGE and PICO, bioactives including SANTYL and GRAFIX PLUS skin substitutes, and advanced wound care dressings like ALLEVYN LIFE. Founded in 1856 and headquartered in Watford, UK, Smith & Nephew plc conducts global operations in approximately 100 countries, targeting surgeons, nurses, physicians and healthcare institutions in established markets including the US, Europe, Japan and emerging markets. In recent developments, the company advances its 12-Point Plan transformation programme, achieving underlying revenue growth of 5.3% to $5.8 billion in 2024, trading profit margin expansion to 18.1%, free cash flow of $551 million and adjusted ROIC of 7.4%, with over 60% of growth from products launched in the past five years including CATALYSTEM Primary Hip System and CORIOGRAPH planning services; it completed the CartiHeal acquisition for the AGILI-C Cartilage Repair Implant, expanded REGENETEN indications to extra-articular ligaments in the US, launched nearly 50 new products over three years, reduced Day Sales of Inventory by 20 days, delivered 410bps in cost savings, cut restructuring costs to $123 million, reorganized around business units for greater accountability, and announced a $500 million share buyback programme commencing August 2025.
Company News
Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets
Smith+Nephew lancia in Europa CARTIHEAL™ AGILI-C™, l'innovativo impianto per la riparazione della cartilagine, che sarà presentato all'ICRS Summit in Portogallo.
Smith+Nephew's revolutionary CARTIHEAL™ AGILI-C™ Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal
Smith+Nephew lanza en Europa el innovador implante de reparación de cartílago CARTIHEAL™ AGILI-C™, que será protagonista en el Congreso ICRS de Portugal
Smith+Nephew Launches EVOS PELVIC System to Advance Trauma Care
Smith & Nephew SNATS (NYSE:SNN) Reaches New 52-Week Low – Time to Sell?
MULTIMEDIA UPDATE: Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management
Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management
Smith+Nephew to showcase leading shoulder technologies for joint repair and reconstruction at ICSES 2026
Smith & Nephew Plc Announces Result of Cash Tender Offer for 2030 Bonds
Smith & Nephew Plc Announces Pricing of Cash Tender Offer for 2030 Bonds
Is It Too Late to Buy Smith & Nephew PLC (SNN) After 3.3% Rally? GF Value Says Undervalued
Smith & Nephew SNATS (NYSE:SNN) Hits New 52-Week Low Following Analyst Downgrade
Smith & Nephew Plc Announces Cash Tender Offer for 2030 Bonds Up To $250m
Smith & Nephew keeps Jefferies 'buy' despite H2 growth scepticism
Panmure Liberum cuts Smith & Nephew target price after disappointing results and CFO exit
UBS cuts Smith & Nephew target on competitive threats to three franchises
BlackRock Inc. Invests $505.32 Million in Smith & Nephew SNATS, Inc. $SNN
SNN Advances Surgical Robotics Through Imperial College Partnership
Smith & Nephew shares slip on CFO's departure